Delivered as a Hybrid Event
Dr. Alexander Hempelmann, PhDGroup Leader ADC Technologies at Heidelberg Pharma Research GmbHSpeaker
Profile
Dr. Alexander Hempelmann is a German structural biochemist specializing in antibody engineering and protein interactions. He currently serves as a Group Leader for ADC Technologies at Heidelberg Pharma in Ladenburg, Germany, where he focuses on advancing antibody-drug conjugate (ADC) platforms. His academic journey includes a Master of Science degree in Biochemistry from Heidelberg University (2015-2018) and prior studies at the University of Göttingen (2012-2015, B.Sc. Biochemistry). He has completed his Ph.D. at the German Cancer Research Center (DKFZ) in Heidelberg, contributing to the Division of Structural Biology of Infection and Immunity. Notable publications include work on immune epitope mapping using nanobodies (Hempelmann et al.2021; Cell Reports [PMID: 34731611], Zeelen et al., 2021; Nature Microbiol. [PMID 33462435]) and COVID-19 diagnostics (Casati et al., 2022; Nature communications [PMID 35676259]). His research focusses on protein engineering and purification, and applied X-ray crystallography and cryoEM. His career reflects a commitment to advancing therapeutic strategies through structural biochemistry and innovative diagnostic solutions. |